Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (1398)	10/27/2006 2:25:20 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

This news about Desmoteplase might help recruitment for the Viprinex trials. The failure of the Renovis drug, NXY-059, on the other hand, isn't a plus for NTII. NXY-059 was a neuroprotectant and might have been a valuable addition to Viprinex (or tPA for that matter) in a drug cocktail approach. Each time a stroke drug fails you worry about building pessimism in the stock market and in the clinical community about finding something that will work. But all should remember that tPA got approved and it is a terrific drug, if you can appply it within its narrow window for intervention after the onset of a stroke. Renovis participated in the Stroke panel that I attended. They gave a very good presentation. I didn't expect that their drug would fail -- just the opposite. Marc